Newsfeeds - Spark Newswire

1 minute read

B. Riley Securities Initiates Coverage On Kymera Therapeutics with Neutral Rating, Announces Price Target of $67

Today, 11:32 PM

B. Riley Securities analyst Kalpit Patel initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Neutral rating and announces Price Target of $67.

KYMR

1 minute read

Stifel Initiates Coverage On Kymera Therapeutics with Buy Rating, Announces Price Target of $80

By Benzinga Newsdesk

Today, 11:32 PM

Stifel analyst Bradley Canino initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Buy rating and announces Price Target of $80.

KYMR

5 minute read

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera’s COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold

By Shanthi Rexaline

Today, 11:32 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)

ABCL

1 minute read

B of A Securities Upgrades Kymera Therapeutics to Buy, Raises Price Target to $80

By Benzinga Newsdesk

Today, 11:32 PM

B of A Securities analyst Geoff Meacham upgrades Kymera Therapeutics (NASDAQ:KYMR) from Neutral to Buy and raises the price target from $65 to $80.

KYMR

1 minute read

Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Lowers Price Target to $68

By Benzinga Newsdesk

Today, 11:32 PM

Morgan Stanley analyst Vikram Purohit maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and lowers the price target from $69 to $68.

KYMR

1 minute read

Kymera Therapeutics Q2 Net Loss $24.7M vs $14M In Same Qtr. Last Year, Sales $18.50M Up From $3.30M YoY

By Benzinga Newsdesk

Today, 11:32 PM

Kymera Therapeutics (NASDAQ:KYMR) reported $18.50 million in sales this quarter. This is a 460.61 percent increase over sales of $3.30 million the same period last year.

KYMR

1 minute read

Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $69

By Benzinga Newsdesk

Today, 11:32 PM

Morgan Stanley analyst Vikram Purohit maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price target from $67 to $69.

KYMR

3 minute read

FDA
News

Kymera Therapeutics Presents New Preclinical Data On STAT3 Degrraders Showing Antitumor Activity In STAT3 Mutant And Wild-Type Peripheral T-Cell Lymphoma At Annual T-Cell Lymphoma Forum

By Benzinga Newsdesk

Today, 11:32 PM

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced new preclinical data

KYMR

3 minute read

The Past Week’s Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More

By Nelson Hem

Today, 11:32 PM

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Initial and secondary public offerings enticed insiders to come out and buy shares this past week. Besides IPOs, biotechs and special purpose acquisition companies are well represented on this week's list.

ABOS

5 minute read

58 Biggest Movers From Yesterday

By Lisa Levin

Today, 11:32 PM

Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share.

ABOS